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Our lab developed 99mTc-NTP 15-5 radiotracer as targeting proteoglycans (PGs) for the scintigraphic imaging of joint. This paper
reports preclinical results of 99mTc-NTP 15-5 imaging of an orthotopic model of Swarm rat chondrosarcoma (SRC). 99mTc-NTP
15-5 imaging of SRC-bearing and sham-operated animals was performed and quantified at regular intervals after surgery and
compared to bone scintigraphy and tumoural volume. Tumours were characterized by histology and PG assay. SRC exhibited
a significant 99mTc-NTP 15-5 uptake at very early stage after implant (with tumour/muscle ratio of 1.61 ± 0.14), whereas no
measurable tumour was evidenced. As tumour grew, mean tumour/muscle ratio was increased by 2.4, between the early and late
stage of pathology. Bone scintigraphy failed to image chondrosarcoma, even at the later stage of study. 99mTc-NTP 15-5 imaging
provided a suitable set of quantitative criteria for the in vivo characterization of chondrosarcoma behaviour in bone environment,
useful for achieving a greater understanding of the pathology.
1. Introduction
Our laboratory has developed the 99mTc-N-[triethylammo-
nium]-3-propyl-[15]ane-N5 (99mTc-NTP 15-5) radiotracer
able to link proteoglycans (PGs) of cartilage, which was
demonstrated to allow scintigraphic imaging of joint [1–
6]. PG appear also as key partners in bone cell biology,
and might represent interesting targets for the assessment
of malignant pathological processes [7]. Chondrosarcoma
represent 25% of all bone sarcoma and are characterized by
the formation of a cartilage like extracellular matrix [8–10].
To the orthopedic oncologists, it is essential to identify the
lesions that are thought to constitute the “cartilage tumour
group”, through the presence of identifiable elements that
resemble the cells and matrix of cartilage. For such analysis,
the three-grade histopathologic classification of Evans is
based on cell type/diﬀerentiation, matrix formation and
architecture, and is at present considered useful for the
prediction of clinical behaviour [11–13]. To date, many
questions still remain unanswered and there is an urgent
need for markers of biologic phenotypic features, that could
be determined in a noninvasive manner, and could be
used as objective criteria of grading, followup, response to
therapy and detection of recurrence. CT and MRI define
morphology, but are limited in distinguished postoperative
residual and postchemotherapeutic lesions due to altered
tissue planes, edema and fibrosis. Contrast-enhanced MRI,
while providing data for local staging and extraosseous
involvment, appears also limiting in determining biologic
behaviour of lesions [14–16]. SPECT by the use of highly
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specific radiolabelled probes, allows a noninvasive and
quantitative assessment of many biochemical pathways in
vivo [17]. In such context, scintigraphic imaging with 99mTc-
NTP 15-5 would be a powerful tool for a direct in vivo
quantitative evaluation of chondrosarcoma at the PG level,
allowing therefore the detection of changes in relation to
pathological processes and/or response to therapies. We
therefore initiated preclinical studies aiming at determining
whether 99mTc-NTP 15-5 imaging could be useful for the
evaluation of the tumoural pathology of cartilage in vivo.
In the present study, the 99mTc-NTP 15-5 imaging was
characterized in the Swarm rat chondrosarcoma implanted
in paratibial location.
2. Materials andMethods
2.1. Animals. Male Sprague Dawley (Charles River, France)
were included in this study. They were handled and cared
for in accordance with the guidelines for the Care and Use
of Laboratory Animals (National Research Council, 1996)
and European Directive 86/809/EEC. They were maintained
at 21◦C with a 12 h/12 h light/dark cycle. Protocols were
performed under the authorisation of the French Direction
of Veterinary Services (Authorisation N◦ C63-113-10) and
conducted by authorized investigators in accordance with
the institution’s recommendations for the use of laboratory
animals.
2.2. Chondrosarcoma Model. The Swarm rat chondrosar-
coma (SRC) line was a generous gift from Dr. P. A. Guerne
(Geneva, Switzerland) as tissue fragments that were frozen
until use.
For tumoural implant, the rats were anaesthetized by
inhalation of a combination isoflurane (Abbott, France)/air
(1.5%, 1 L/min) associated with an intramuscular injection
of 100mg/kg ketamine (Imalgene, Rhone Merieux, France).
Allograft transplantation of a tumour fragment (10
animals) was performed on the right paw, the other paw
being used as the controlateral reference, as previously
published [18].
Using a lateral approach, the cortical surface of the dia-
physis was scarified laterally on 10mm, a 10mm3 fragment
of SRC was placed contiguous to the scarified surface, and
the muscular and cutaneous wounds were sutured. The same
procedure was performed for the controlateral paw, but no
tumour fragment was implanted. Tumours appeared at the
graft site 7–11 days later.
2.3. Establishment of the Sham Model. Five animals under-
went sham surgery, in which the right paw was submitted to
the same surgery procedure as SRC animals, but no tumour
fragment was implanted.
2.4. Acquisitions for 99mTc-NTP 15-5 Imaging. Scintigraphic
in vivo imaging was performed using a small-animal γ cam-
era (CsI(Na) crystal) equipped with a 1.3/0.2/35 parallel-hole
collimator (hole diameter/septum thickness/height in mm)
(Gammaimager, Biospace, France). The energy resolution
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Figure 1: Chemical structure of 99mTc-N-[triethylammonium]-3-
propyl-[15]ane-N5 (99mTc-NTP 15-5).
and intrinsic planar resolution of the system are given as 11%
at 140 keV and<2mm full width at half maximum (FWHM),
respectively.
The radiotracer 99mTc-NTP 15-5 (Figure 1) radiotracer
was prepared and radiolabelled as previously published
[1–6], and administered by IV route to vigil animals
(25Mbq/animal) using dedicated contention box.
First of all, a 10-min planar acquisition (with a 15%
window centered on the 140 keV photopeak of 99mTc) was
performed on 3 animals with a well-established tumour
(volume = 949.35 ± 223mm3) at several intervals (30,
60, 90 and 120mins) to determine kinetics of tracer accu-
mulation within chondrosarcoma, respectively, to articular
cartilage and muscle. For acquisition, each posterior paw of
animals was positioned over the collimator of the camera
as illustrated in Figure 2. Quantitative analysis of scinti-
graphic scans was performed using the GAMMAVISION+
software (Biospace, France). Regions of interest (ROIs)
were delineated over tumour, femorotibial cartilage and
muscle patterns. For each animal and each ROI, average
count in cpm per pixel was obtained. Two semiquantitative
parameters were determined:
T
M
= average count in tumour
average count in muscle
,
T
C
= average count in tumour
average count in femorotibial cartilage
.
(1)
Data were expressed as mean ± standard deviation.
A serial imaging was then performed on primary
chondrosarcoma-bearing rats (n = 10) and sham-operated
animals (n = 5) at regular intervals after surgery (from
day 4 to day 35), with 10-min planar acquisition being
started 30mins after iv administration of 99mTc-NTP 15-
5. Scintigrams were considered positive when tracer uptake
areas corresponded to sites of implant. All the positive
scans were evaluated using the ROI method as described
above, with T/C and T/ M parameters being determined
for each animal at each time point, and data expressed as
mean ± standard deviation. Semi-quantitative parameters
determined at day 4 were used as the “threshold reference
value” and were compared to the mean values determined at
each time point of study (paired 2-sided Student t-test with
a level of significance set at P < .05).
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Figure 2: In vivo scintigraphic acquisition of chondrosarcoma bearing rats using a small animal dedicated gamma camera.
2.5. Acquisitions for 99mTc-HMDP Bone Imaging. Primary
chondrosarcoma-bearing rats were also submitted to bone
scintigraphies at day 12, day 38, and day 48 after implant.
For each paw, “delayed images” (10-minute duration) were
acquired 2 hours post injection of 99mTc-HMDP radiotracer
(Osteocys, IBA, France; 30MBq/animal).
Bone scintigrams were considered positive when tracer
uptake areas corresponded to sites of implant.
2.6. Tumour Growth Assessment. The tumour volume was
determined from the measurement of 2 perpendicular diam-
eters using a calliper. Tumour volumes (V) were calculated
according to the following formula:
V
(
mm3
) = 0.5× L× (S)2, (2)
where L and S are, respectively, the largest and smallest
perpendicular tumour diameters in mm [19].
2.7. Histology of SRC Tissue. At the end of the study, three
chondrosarcoma-bearing rats were killed for histological
characterization of the tumours. The femora and tumour
of each rat were removed and fixed at 4◦C for 48 hours in
formol buﬀer (pH 7.4). The femora where cut longitudinally
or transversally. Decalcified femoral fragments were embed-
ded in paraﬃn and 5 μm sections were mounted on glass
slides for staining with Hematoxylin-Eosin-Safran (HES)
and Alcian blue.
2.8. PG Content of SRC Tissue. At the end of the study,
SRC were removed (n = 3 animals), dissected and digested
for 24 h at 60◦C with EDTA-phosphate buﬀer solution
containing Papaine 0.60mg/mL (Sigma-Aldrich, France)
and DL-dithiothreitol (DTT) 0.25mg/mL (Sigma-Aldrich,
France). Digests were then assessed for PG content using the
dimethylene blue protocol [20].
PG content of SRC tissue was compared to PG content
of mouse B16F0 melanoma as negative control: B16F0
melanoma were removed from bearing mice (n = 3) (stage
day 15 after subcutaneous inoculation of 300000 B16F0
cells), and submitted to the same procedure of extraction and
digestion as SRC tumours.
3. Results
3.1. SRC Characterisation: Tumoural Growth, Histology and
PG Assay. Tumour volumes were followed for 35 days
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Figure 3: Tumour volume growth for Swarm rat chondrosarcoma
(SRC) implanted in paratibial location. Mean values + standard
deviation are presented at each time point.
after primary implant (Figure 3). All the animals developed
a tumour that became palpable from day 10. Histolog-
ical examination (Figure 4(a)) at study end evidenced a
chondroid tumoural tissue, poorly vascularized, lobular in
organization with lobules containing chondroid stroma and
delimited by fine fibrous septa. Hypercellularity was also
observed. At this later stage of pathology, an extensive
invasion of bone and surrounding tissues was present, as well
as osteolysis.
The overall presence of PG was first investigated by
Alcian blue staining: as shown in Figure 4(b), a high density
of stained areas were observed in SRC tissue, revealing the
presence of PG in this tumour.
PG content of SRC tumour tissue was also assessed by
biochemical dosage. PG content of SRC tissue was compared
with PG of murine B16F0 melanoma tumour as negative
control: As shown in Figure 5, a high PG content was
observed in SRC tissue (7.46 ± 2.41 μg of PG/mg of tissue),
respectively, to melanoma (0.45 ± 0.16 μg of PG/mg of
tissue).
3.2. 99mTc-NTP 15-5 Distribution in SRC Tissue, Respectively,
to Muscle and Cartilage. 99mTc-NTP 15-5 distribution in
well-established primary chondrosarcomas was character-
ized at 30, 60, 90 and 120mins after 99mTc-NTP 15-5
administration, on the basis of tumour/muscle (T/M) and
tumour/cartilage (T/C) ratios. As shown in Figure 6(a),
99mTc-NTP 15-5 rapidly accumulated within SRC tissue,
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(a) (b)
Figure 4: Histomorphological features of the SRC model at study end showing: (a) a tumoural tissue with hypercellularity, and bone
osteolysis (x10); (b) a high density of blue Alcian stained areas as a reflect of proteoglycan content (x5).
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Figure 5: PG content of SRC tissue, respectively, to murine
melanoma tumour (as negative control); Mean values + standard
deviation are presented.
with T/M and T/C ratios being 1.44 ± 0.27 and 0.78 ±
0.03 from 30mins post injection. Radiotracer accumulation
within tumoural tissue was observed to be as high as in
cartilage tissue from 60mins pi, with T/C value of 0.90 ±
0.23. No significant changes were observed in T/M and T/C
ratios from 60 to 120mins pi.
This high and selective accumulation of 99mTc-NTP 15-
5 within tumour was at the origin of the highly contrasted
chondrosarcoma imaging in vivo, as shown in (Figure 6(b))
for a representative animal.
3.3. Diagnosis Capability of 99mTc-NTP 15-5 Imaging,
Respectively, to 99mTc-HMDP Bone Scintigraphy and Calliper
Measurement. All the implanted animals were positive for
chondrosarcoma at necropsy.
Figure 7 shows the disease incidence according to 99mTc-
HMDP scintigraphy, 99mTc-NTP 15-5 imaging, and calliper
measurement during the whole study of monitoring.
A palpable and measurable tumour was observed from
day 10 after implant for 50% of the animals. From day 20,
100% of the animals evidenced measurable tumours.
99mTc-NTP 15-5 scintigraphy was positive for 66.66% of
the animals as early as day 4 post implant, and for 100% of
the animals from day 10.
99mTc-HMDP bone scintigraphy was negative for SRC
imaging during the whole duration of study, and even later
(48 days post implant).
3.4. Monitoring of SRC Growth In Vivo Using 99mTc-NTP 15-5
Imaging. As shown in Figure 8 for a representative animal,
99mTc-NTP 15-5 radiotracer was observed to accumulate
within tumoural tissue, respectively, to the contralateral paw
(Figure 8(a)), as early as day 4 after implant: scintigram
of the tumour bearing paw (Figure 8(b)) evidenced (i)
uptake areas in femorotibial articular cartilage, with the
tibial plateau uptake clearly distinguished from the femoral
condyle uptake, (ii) accumulation at the site of implant.
99mTc-NTP 15-5 examination of the same animal at late stage
of pathology (day 35, Figure 8(c)) evidenced that radiotracer
accumulation within the tumour-bearing paw was highly
increased, respectively, to day 4.
99mTc-NTP 15-5 accumulation was quantitatively
assessed in vivo in the tumour, respectively, to muscle and
cartilage (as T/M and T/C uptake ratios, resp.) as a function
of time after implant (Figure 9): As early as day 4 post
implant, the mean T/M and T/C values were 1.61 ± 0.14 and
0.57 ± 0.06, respectively. From day 10, tumoural uptake of
99mTc-NTP 15-5 was as high as cartilage uptake with T/C =
1.08 ± 0.09; T/M value was 2.55 ± 1.15.
At study ending (day 35), mean T/C and T/M values were
1.61 ± 0.06 and 3.97 ± 0.74, respectively.
3.5. Monitoring of Sham-Operated Animals Using 99mTc-NTP
15-5 Imaging. Serial 99mTc-NTP 15-5 imaging of sham-
operated animals (n = 5) performed over 50 days after
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Figure 6: 99mTc-NTP 15-5 in vivo distribution in chondrosarcoma;
(a) 99mTc-NTP 15-5 uptake ratios as a function of delay between
iv administration of tracer and acquisition; (b) Scintigraphic image
obtained for a representative animal, for a delay of 30min between
injection and acquisition. Abbreviations: F: femoral condyle; T:
tibial plateau; CHS: chondrosarcoma.
surgery did not evidence any accumulation of the tracer at
site of surgery.
4. Discussion
This experimental study was conducted in the syngeneic
model of SRC that has been the subject of extensive
biochemical studies on extracellular matrix and chondrocyte
metabolism [21, 22]. Histological characterization of SRC
implanted in paratibial location, evidenced a chondroid
tumoural tissue, poorly vascularized, lobular in organization
with lobules containing chondroid stroma delimited by fine
fibrous septa. In the present study PG were confirmed (by
both alcian blue staining and biochemical assay) as being a
major component of SRC tissue. The high concentration of
PG in the tumour is at the origin of a high density of ECM
strong negative charges that may interact with the positively
charged quaternary ammonium moiety of the 99mTc-NTP
15-5 radiotracer. The ability of 99mTc-NTP 15-5 to image
SRC tissue was therefore demonstrated from 30mins post
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Figure 7: Disease incidence at each time point of study, according to
99mTc-HMDP scintigraphy, 99mTc-NTP 15-5 imaging, and calliper
measurement.
injection with T/M and T/C ratios being 1.44± 0.27 and 0.78
± 0.03.
Interestingly, tracer accumulation was detected at early
stage (day 4) and for about 70% of the animals investigated,
whereas no palpable nor measurable tumour was evidenced.
Such early accumulation raised the question of whether the
imaging pattern represented an eﬀective tumoural uptake or
a surgery-induced inflammation. Negative 99mTc-NTP 15-5
imaging observed for sham-operated animals definitely ruled
out the hypothesis of inflammation contribution.
99mTc-NTP 15-5 accumulation within SRC was assessed
at multiple time-points of tumoural growth using a semi-
quantitative method. As tumour developed over time, mean
T/M and T/C values were observed to be increased by a factor
of 2.4 and 2.8, respectively, between the early stage day 4
and the late stage day 35. Tumour to femorotibial cartilage
uptake ratio (T/C parameter) is of particular importance
for clinical application (in patients, tumour is located in the
joint). From our results, the increase in T/C with pathology
argued in favour of a high tumour/cartilage contrast which
would expect diagnosis of tumour occurrence within the
joint.
Another interesting result of this study is that 99mTc-
HMDP bone scintigraphy commonly used in clinical practise
failed to image tumoural tissue throughout the study,
whereas 99mTc-NTP 15-5 imaging was positive.
These preclinical results underlined the suitability and
high sensitivity of 99mTc-NTP 15-5 scintigraphic imaging for
assessing in vivo the PG component of chondrosarcomas,
providing therefore criteria for a quantitative and functional
assessment of the tumoural pathology in vivo.
Our results raised the question of whether 99mTc-NTP
15-5 imaging patterns in benign cartilage tumours, (which
are known to form a cartilaginous PG—rich matrix), would
be the same as for malignant tumours. According to many
histological studies, the neoplastic cells of benign cartilage
tumours such as chondroblastoma did not show, at any point
of their evolution, real cartilagematrix formation [13, 23]. As
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Figure 8: 99mTc-NTP 15-5 longitudinal in vivo examination of a representative SRC-bearing rat; (a) in vivo scintigraphic image of the
contralateral paw at day 4; (b) in vivo scintigraphic image of the tumour-bearing paw at day 4; (c) in vivo scintigraphic image of the tumour
bearing paw of the same animal at day 35. A clear accumulation of radioactivity within tumoural tissue was observed as early as day 4 after
implant (Image b, arrow); abbreviations: CHS = chondrosarcoma.
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a consequence, a diﬀerential accumulation of 99mTc-NTP 15-
5 radiotracer could be expected. Since the biological nature
of benign cartilage tumours is still debating, we will have
to elucidate this aspect by performing a preclinical 99mTc-
NTP 15-5 imaging study of rodent models of enchondroma,
(such as mutant mice for hedgehog signalling pathways
or Ext1/Ext2 exostosin encoding gene) in parallel to the
biological characterization of PG of tissue [23–25].
From a clinical point of view, the distinction between
benign and low-grade malignant pathology, is known to be
extremely diﬃcult both at radiologically and histologically,
and remains a challenge [9, 26]. All current imaging
modalities have shown their limitations. Radiographs, CT,
MRI and contrast enhanced MRI provide morphological
data for local staging and extra-osseous involvement, but
appeared limited in determining functional markers of
postoperative recurrence, response or relapse to therapies
[9, 27–29]. In such context, 99mTc-NTP 15-5 radiotracer
may serve as an adjunct to CT and MRI, by supplying
quantitative data which would allow imaging and follow-
up to be functionally rather than morphologically based.
For functional imaging of cartilage neoplasms, radiotracers
currently available provide indirect evaluations of the pathol-
ogy, such as bone remodeling and inflammation features,
but do not allow biological assessment of the tumour. Many
tumour seeking agents such as 201Tl, 99mTc-MIBI, 99mTc-
Tetrofosmin, 99mTc-DMSA(V) and more recently 18F-FDG
have been found useful in an initial diagnosis and grading,
but they have also demonstrated their limitations for imaging
chondrosarcoma with low cellularity and low vascularity
[30–33]. 99mTc-NTP 15-5 imaging would allow a regular in
vivo follow up, in order to evidence any “upregulation” or
“downregulation” synthesis of PG, as the reflect of potential
malignant transformation, recurrence, response or relapse to
therapies. We strongly believe in such potential application
since 99mTc-NTP 15-5 imaging recently evidenced in the SRC
model a “downregulation synthesis” of PG as a result of
anticancer treatment (unpublished data).
Another potential application of 99mTc-NTP 15-5 imag-
ing in chondrosarcoma would be the early imaging of metas-
tasis. As a consequence, the sensitivity of 99mTc-NTP 15-5
imaging for the early evaluation of chondrosarcomametasta-
sis has to be determined in relevant preclinical animalmodels
of chondrosarcoma with spontaneous metastasis [34, 35].
5. Conclusion
This preliminary work in the orthotopic SRC model under-
lined the suitability and high sensitivity of 99mTc-NTP
15-5 radiotracer for imaging chondrosarcoma at the PG
level. 99mTc-NTP 15-5 imaging provided a suitable set
of quantitative criteria for the in vivo characterization of
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chondrosarcoma behaviour in bone environment, which
could be useful for achieving a greater understanding of the
pathology.
In view of a potential clinical application, 99mTc-NTP 15-
5 imaging appears of interest for (i) the establishment of the
cartilaginous nature of “musculoskeletal” tumours (ii) the in
vivo assessment to PG changes associated to the evolution
of pathological process, local recurrence, response or relapse
to therapies. Additional preclinical studies are needed to
investigate the potential of 99mTc-NTP 15-5 imaging in the
tumoral pathology of cartilage.
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